Baillie Gifford acquired 16.7M Dexcom shares worth $1.35B. That's 0.97% of their equity portfolio (25th largest holding). The investor owns 4.57% of the outstanding Dexcom stock. The first Dexcom trade was made in Q1 2013. Since then Baillie Gifford bought shares sixteen more times and sold shares on 32 occasions. The stake costed the investor $628M, netting the investor a gain of 115% so far.